Invention Grant
- Patent Title: Anti-CD47 antibody molecules
-
Application No.: US16543884Application Date: 2019-08-19
-
Publication No.: US10683350B2Publication Date: 2020-06-16
- Inventor: William James Jonathan Finlay
- Applicant: ULTRAHUMAN FOUR LIMITED
- Applicant Address: GB Sandwich
- Assignee: ULTRAHUMAN FOUR LIMITED
- Current Assignee: ULTRAHUMAN FOUR LIMITED
- Current Assignee Address: GB Sandwich
- Agency: Cooley LLP
- Agent Ivor R. Elrifi
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@b317d6 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@7aef12a com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@62a4dd72
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K16/30 ; A61P35/00 ; A61K39/395

Abstract:
The invention relates to antibody molecules and antigen-binding portions thereof which bind specifically to CD47 (Cluster of Differentiation 47, also known as integrin associated protein [IAP]). In aspects of the invention, the anti-CD47 antibody molecules and antigen-binding portions thereof specifically bind to human CD47 and cynomolgus monkey CD47. Medical uses of the anti-CD47 antibody molecules and antigen-binding portions of the invention are disclosed. The anti-CD47 antibody molecules and antigen-binding portions of the invention represent modified and optimised binding molecules compared with a VxP037 murine/humanized anti-CD47 antibody described in WO2014/093678A2.
Public/Granted literature
- US20190375840A1 BINDING AGENTS Public/Granted day:2019-12-12
Information query